Status:
COMPLETED
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Cocaine Addiction
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to assess the efficacy and safety of TV-1380 \[Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)\] in facilitating abstinence in coc...
Eligibility Criteria
Inclusion
- Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol.
- Male or female aged 18-60 years (inclusive).
- Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
- Other criteria apply; please contact the site for more information.
Exclusion
- Meet criteria for current dependence on any psychoactive substance other than cocaine, alcohol, nicotine, benzodiazepines, or marijuana OR have physiological dependence on alcohol requiring detoxification.
- Are currently treated with an opiate-substitute (buprenorphine or methadone) maintenance treatment or received therapy with any opiate-substitute within 90 days preceding screening.
- Have one or more severe psychiatric disorders as determined by the Mini International Neuropsychiatric Interview (MINI) such as psychosis, schizophrenia, bipolar disease, major depression, or eating disorders in screening.
- Have one or more major neurologic disorders such as dementia or organic brain disease.
- Have other serious medical illnesses (including but not limited to uncontrolled hypertension, significant heart disease, respiratory disease including asthma, hepatic disease, renal disease, AIDS) or other potentially life threatening or progressive medical illness that may compromise subject safety or study conduct as determined by the site MD.
- Other criteria apply; please contact the site for more information.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT01887366
Start Date
June 1 2013
End Date
October 1 2014
Last Update
November 5 2015
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Teva Investigational Site 10663
Los Angeles, California, United States
2
Teva Investigational Site 10665
Oceanside, California, United States
3
Teva Investigational Site 10659
San Francisco, California, United States
4
Teva Investigational Site 10746
Torrance, California, United States